Optus Pharmaceutical Co. Ltd.

04/26/2024 | Press release | Distributed by Public on 04/25/2024 23:36

Interim Report on Business Performance(Fair Disclosure)

Interim Report on Business Performance(Fair Disclosure)
※ The information contained in this report is estimated, it is subject to change according to actual settlement.
1. Business Results
Classification(Unit : Mil. KRW, %) Current Period Preceding Period Amount Increased/Decreased Compared to the Preceding Period(Increase/Decrease Rate) Corresponding Period of The Previous Year Amount Increased/Decreased Compared to the Corresponding Period of The Previous Year (Increase/Decrease Rate)
(2024.01.01~ 2024.03.31) (2023.10.01~ 2023.12.31) (2023.01.01~ 2023.03.31)
Sales Amount 18,679 19,880 -1,201
(-6.0) 		16,900 1,779
(10.5)
Accumulated Amount 18,679 - - 16,900 1,779
(10.5)
Operating Income Amount 2,235 1,921 314
(16.3) 		1,610 625
(38.8)
Accumulated Amount 2,235 - - 1,610 625
(38.8)
Profit from continuing operation before corporate income tax Amount 2,924 3,621 -697
(-19.2) 		2,517 407
(16.2)
Accumulated Amount 2,924 - - 2,517 407
(16.2)
Net Income Amount 2,403 3,167 -764
(-24.1) 		2,050 353
(17.2)
Accumulated Amount 2,403 - - 2,050 353
(17.2)
- - - - - -
2. Selective Release Information Providers 경영지원부
Intended Audience 기관투자자,언론사,애널리스트,일반주주 등
Date and Time of Information Release 공정공시 후 수시제공
(Scheduled) Time and Place for Release of Information -
3. Contact Information Person Responsible for Disclosure(Contact Information) 김광훈CFO (02-2118-0030)
Person in Charge of Disclosure(Contact Information) 이현종 부서장 (02-2118-0030)
Office in Charge(Contact Information) 경영지원부 (02-2118-0030)
4. Other references concerning investment decisions 1. 상기 실적은 한국채택국제회계기준(K-IFRS)에 따라 작성된 개별기준 영업(잠정)실적입니다.

2. 상기 실적자료는 외부감사인의 검토를 받지 아니한 내부결산 자료이며, 향후 일부 변동될 수 있습니다.

3. 관련 자료는 당사 홈페이지(http://www.optuspharm.com)'IR 및 공고자료' 게시판에 게재 및 IR 자료로 활용될 예정입니다.
※Relevant Disclosure -